Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study

Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP

Read the full article

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.